Apellis
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
141 Camberwell Rd, Hawthorn East, Victor...Website
www.geographicatrophy.com.auRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Apellis
Apellis is a global biopharmaceutical company focused on developing life-changing medicines through innovative science and compassion. They specialize in targeted C3 therapies aimed at addressing a range of debilitating diseases, particularly in the fields of ophthalmology, haematology, nephrology, and neurology. The company is dedicated to addressing the unmet medical needs associated with geographic atrophy, a severe form of age-related macular degeneration that leads to irreversible vision loss. Apellis provides resources and educational materials specifically for healthcare professionals in Australia to enhance their understanding of geographic atrophy and its impact on patients.Explore more
Popular SearchesApellisSIC Code 28,283NAICS Code 32,325Show moreApellis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apellis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Apellis has new funding data
Congratulate Masked Content for being promoted to Masked Content at Apellis
Apellis, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Apellis has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Apellis is spiking on competitors!
Earning: See what the market has to say on Apellis recently announced quarterly report
Product Launch: Get notified when Apellis launches new products
Click to see if Apellis had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Apellis as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Apellis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Apellis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Apellis.
Apellis News & Media
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.Apellis Pharmaceuticals Gains Boost from Analysts and Leadership Changes
Apellis Pharmaceuticals Inc.’s stocks have been trading up by 135.75 percent, driven by promising FDA designations and results. Key Takeaways Roth Capital’s positive views on Syfovre demand led to a Buy rating and a promising price target. Apellis Pharmaceuticals strengthens R&D capabilities with the addition of Mikael Dolsten. Positive long-term market share trends identified for […]Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Apellis Pharmaceuticals, Inc. (APLS) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM ESTCompany ParticipantsCedric Francois - Co-Founder,...
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Apellis
Sign Up For FreeTo access detailed company insights
Apellis is a global biopharmaceutical company focused on developing life-changing medicines through innovative science and compassion. They specialize in targeted C3 therapies aimed at addressing a range of debilitating diseases, particularly in the fields of ophthalmology, haematology, nephrology, and neurology. The company is dedicated to address... Read More
